1
|
Jiang X, Hu Y, Qu XP, Xu DW, Jiang H, Li CM, Jiang H, Wang DL, Li G, Zhu XG, Liu B. Prediction of in-hospital recurrence and false-negative results in patients with COVID-19 by red blood cell values on admission. Exp Ther Med 2021; 22:1250. [PMID: 34539846 PMCID: PMC8438694 DOI: 10.3892/etm.2021.10685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 04/26/2021] [Indexed: 01/08/2023] Open
Abstract
The clinical characteristics and risk factors of patients with coronavirus disease 2019 (COVID-19) with re-positive or false-negative test results have so far remained to be determined. The present study provides a cross-sectional observational study on 134 hospitalized patients selected from Huoshenshan Hospital (Wuhan, China) using cluster sampling. A total of 68 patients had reduced red blood cell (RBC) counts, 55 a decrease in the hemoglobin concentration (HBC) and 73 a decline in hematocrit (HCT). The false-negative rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA detection in pharyngeal swab specimens was 18.7%. The absolute lymphocyte count (ALC), RBC, HBC and HCT levels in false-negative patients were significantly higher than those in patients who tested positive for viral nucleic acids. Multivariate logistic regression analysis indicated that RBC [odds ratio (OR)=0.43, 95% CI: 0.18-0.99], HBC (OR=0.97, 95% CI: 0.94-0.99) and ALC (OR=0.43, 95% CI: 0.20-0.91) were the factors influencing the negative testing results for viral nucleic acid. The rate of re-positive patients was 16.4%. The white blood cell, RBC, HBC and HCT values in re-positive patients were lower than those in non-re-positive patients. The median (interquartile range) values for RBC, HBC and HCT of male re-positive patients were 3.95 (3.37, 4.2) x1012/l, 123 (103, 133) g/l and 36.6 (31.1, 39.2)%, respectively, while the RBC, HBC and HCT of female re-positive patients were 3.54 (3.13, 3.74) x1012/l, 115 (102, 118) g/l and 34.2 (28.5, 34.9)%, respectively. It was determined that RBC, HBC and HCT values had moderate accuracy in predicting SARS-CoV-2 recurrence in patients with COVID-19 using receiver operating curve analysis. The present study suggested that RBC may have an important role in the pathogenesis of COVID-19.
Collapse
Affiliation(s)
- Xue Jiang
- Third Department of Infectious Diseases, Huoshenshan Hospital, Joint Logistics Support Force of The Chinese People's Liberation Army, Wuhan, Hubei 430101, P.R. China.,Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Yan Hu
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China.,Department of Neurosurgery, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330008, P.R. China
| | - Xiao-Peng Qu
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Dong-Wei Xu
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Hong Jiang
- Third Department of Infectious Diseases, Huoshenshan Hospital, Joint Logistics Support Force of The Chinese People's Liberation Army, Wuhan, Hubei 430101, P.R. China.,Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Chun-Mei Li
- Third Department of Infectious Diseases, Huoshenshan Hospital, Joint Logistics Support Force of The Chinese People's Liberation Army, Wuhan, Hubei 430101, P.R. China.,Department of Respiratory Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Hua Jiang
- Third Department of Infectious Diseases, Huoshenshan Hospital, Joint Logistics Support Force of The Chinese People's Liberation Army, Wuhan, Hubei 430101, P.R. China.,Department of Respiratory Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Da-Li Wang
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Gang Li
- Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| | - Xin-Gen Zhu
- Department of Neurosurgery, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330008, P.R. China
| | - Bei Liu
- Third Department of Infectious Diseases, Huoshenshan Hospital, Joint Logistics Support Force of The Chinese People's Liberation Army, Wuhan, Hubei 430101, P.R. China.,Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038, P.R. China
| |
Collapse
|
2
|
Habib S, Meister E, Habib S, Murakami T, Walker C, Rana A, Shaikh OS. Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res 2015; 8:237-246. [PMID: 27785303 PMCID: PMC5051041 DOI: 10.14740/gr686w] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/24/2015] [Indexed: 12/20/2022] Open
Abstract
Background The natural course of hepatic fibrosis in HCV allograft recipients with sustained virological response (SVR) after anti-HCV therapy remains debatable. The aim of this study was to examine the progression of fibrosis in a cohort of patients who achieved SVR compared with those without treatment. Methods The 167 patients who met the inclusion and exclusion criteria were chosen from a transplant database. All patients were required to have histological evidence of recurrent HCV infection post-liver transplantation and a follow-up biopsy. The 140 of these patients had received anti-viral therapy. Twenty-seven patients were identified as controls and were matched with the treatment group in all respects. The patients were categorized into four groups based on treatment response: 1) no treatment (control) (n = 27); 2) non-responders (n = 81); 3) relapsers (n = 32); and 4) SVR (n = 27). The endpoint was the stage of fibrosis on the follow-up liver biopsy. Results The treated and untreated groups were similar in clinical characteristics at the time of transplantation and prior to the initiation of treatment. The 72% of the cohort showed a fibrosis progression of ≥ 1 stage; this change did not significantly differ between the patient groups. Nonetheless, the fibrosis progression rate was the highest in the untreated group and lowest in the patients who achieved SVR. A coefficient of determination was used. Improvements in fibrosis scores were found with greater treatment duration. These improvements were most evident with the achievement of SVR. Conclusions In conclusion, SVR after anti-viral therapy for recurrent hepatitis C infection post-transplantation was associated with slower fibrosis progression and significantly improved graft survival.
Collapse
Affiliation(s)
- Shahid Habib
- Liver Institute, Department of Internal Medicine, Divisions of Gastroenterology, Hepatology and Transplantation, University of Arizona, AZ, USA
| | | | - Sana Habib
- Liver Institute, Department of Internal Medicine, Divisions of Gastroenterology, Hepatology and Transplantation, University of Arizona, AZ, USA
| | - Traci Murakami
- Liver Institute, Department of Internal Medicine, Divisions of Gastroenterology, Hepatology and Transplantation, University of Arizona, AZ, USA
| | - Courtney Walker
- Liver Institute, Department of Internal Medicine, Divisions of Gastroenterology, Hepatology and Transplantation, University of Arizona, AZ, USA
| | - Abbas Rana
- Division of Transplantation Surgery, Department of Surgery, Baylor College of Medicine, TX, USA
| | - Obaid S Shaikh
- Division of Transplantation Surgery and Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| |
Collapse
|